Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at ...
Moving to a subQ formulation makes sense, if you want to be 100% convenient for patients and the centers that treat them, explains Xavier Leleu, MD, PhD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results